<- Go Home
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Market Cap
$168.5M
Volume
722.7K
Cash and Equivalents
$13.0M
EBITDA
-$46.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$27.5M
Profit Margin
79.97%
52 Week High
$5.20
52 Week Low
$1.26
Dividend
N/A
Price / Book Value
0.93
Price / Earnings
-3.67
Price / Tangible Book Value
0.96
Enterprise Value
$81.0M
Enterprise Value / EBITDA
-1.87
Operating Income
-$50.5M
Return on Equity
23.19%
Return on Assets
-13.66
Cash and Short Term Investments
$105.7M
Debt
$18.2M
Equity
$180.3M
Revenue
$34.4M
Unlevered FCF
-$18.3M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium